CN103463022B - Application of Lycojaponicumin B in medicine for treating ileocecum cancer - Google Patents
Application of Lycojaponicumin B in medicine for treating ileocecum cancer Download PDFInfo
- Publication number
- CN103463022B CN103463022B CN201310435560.5A CN201310435560A CN103463022B CN 103463022 B CN103463022 B CN 103463022B CN 201310435560 A CN201310435560 A CN 201310435560A CN 103463022 B CN103463022 B CN 103463022B
- Authority
- CN
- China
- Prior art keywords
- lycojaponicumin
- application
- medicine
- ileocecum cancer
- cancer
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Expired - Fee Related
Links
Landscapes
- Medicines Containing Plant Substances (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Abstract
The invention discloses an application of Lycojaponicumin B in preparation of a medicine for treating ileocecum cancer, belonging to the technical field of new applications of medicines. According to the application disclosed by the invention, the in-vitro MTT (methyl thiazolyl tetrazolium) anti-tumor activity evaluation discovers that the Lycojaponicumin B also has an obvious inhibitory effect on the growth of a human ileocecum cancer cell strain HCT-8. Thus, the Lycojaponicumin B can be used for preparing an ileocecum cancer resisting medicine and has good prospects in development and application. The application of the Lycojaponicumin B in preparation of the medicine for treating ileocecum cancer, disclosed by the invention, is disclosed for the first time. The skeleton type of the Lycojaponicumin B belongs to a brand new skeleton type, and the inhibitory activity of the Lycojaponicumin B on human ileocecum cancer cells is unexpectedly strong.
Description
Technical field
The present invention relates to the novelty teabag of compound L ycojaponicumin B, particularly relate to the application of Lycojaponicumin B in the anti-blindgut cancer of preparation.
Technical background
Cancer is to one of maximum disease of human life's health hazard, has a large amount of people to die from cancer every year.The research and development of cancer therapy drug are the focuses of study of pharmacy always.74% is had to be natural product or derivatives thereof in antitumor drug, if paclitaxel and derivant thereof are exactly the current reasonable antitumor drug of effect clinically.Therefore, from natural product, anticancer compound is found or lead compound has great importance.
The compound L ycojaponicumin B that the present invention relates to is one and delivers (Wang in 2012, X.J.et al., 2012.Lycojaponicumins A-C, Three Alkaloids with an Unprecedented Skeleton from Lycopodiumjaponicum.Organic Letters 14 (10), New skeleton compound 2614-2617.), this compound has brand-new framework types, the purposes of the Lycojaponicumin B that the present invention relates in preparation treatment blindgut cancer is belonged to first public, because framework types belongs to brand-new framework types, and its inhibit activities for ileocecum cancerous cell is unexpectedly strong, there is not the possibility being provided any enlightenment by other compounds, possesses outstanding substantive distinguishing features, control simultaneously for ileocecum cancer obviously has significant progress.
Summary of the invention
The invention provides compound L ycojaponicumin B and prepare the application in antitumor drug.
The present invention adopts following technical scheme: the application of Lycojaponicumin B in the anti-blindgut cancer of preparation, and the structural formula of Lycojaponicumin B is as shown in formula I:
The present invention is found by external MTT antineoplastic activity evaluation, and the growth of Lycojaponicumin B to human ileocecal carcinoma cell strain HCT-8 also has significant inhibitory action, suppresses the IC of this 1 strain Growth of Cells
50value is 1.33 ± 0.11 μMs.Therefore, Lycojaponicumin B for the preparation of anti-blindgut cancer, can have good development prospect.
The purposes of the Lycojaponicumin B that the present invention relates in preparation treatment blindgut cancer belongs to first public, because framework types belongs to brand-new framework types, and its inhibit activities for ileocecum cancerous cell is unexpectedly strong, there is not the possibility being provided any enlightenment by other compounds, possess outstanding substantive distinguishing features, the control simultaneously for ileocecum cancer obviously has significant progress.
The present invention is further detailed explanation by the following examples, but protection scope of the present invention is not by any restriction of specific embodiment, but be limited by claim.
Detailed description of the invention
The preparation method of compound L ycojaponicumin B involved in the present invention is see document (Wang, X.J.et al., 2012.Lycojaponicumins A-C, Three Alkaloids with an Unprecedented Skeleton from Lycopodium japonicum.OrganicLetters 14 (10), 2614-2617.).
The present invention is further detailed explanation by the following examples, but protection scope of the present invention is not by any restriction of specific embodiment, but be limited by claim.
Embodiment 1: the preparation of compound L ycojaponicumin B tablet involved in the present invention:
Get 20 g of compound Lycojaponicumin B, add the customary adjuvant 180 grams preparing tablet, mixing, conventional tablet presses makes 1000.
Embodiment 2: the preparation of compound L ycojaponicumin B capsule involved in the present invention:
Get 20 g of compound Lycojaponicumin B, add prepare capsule customary adjuvant as starch 180 grams, mixing, encapsulatedly makes 1000.
Its pharmaceutically active is further illustrated below by pharmacodynamic experiment.
Experimental example: adopt mtt assay assessing compound Lycojaponicumin B to the growth inhibited effect of human ileocecal carcinoma cell strain
1. method: the cell being in growth logarithmic (log) phase: human ileocecal carcinoma cell strain HCT-8 (buying from Chinese Academy of Sciences's cell bank) is with 1.5 × 10
4concentration kind is in 96 orifice plates.Original culture medium is sucked after cell culture 24h is adherent.Test is divided into blank group, drug treating group.Blank group changes 1640 culture medium containing 10% hyclone; It is 100 μMs that drug treating group is changed containing concentration, 50 μMs, 10 μMs, 1 μM, 0.1 μM, 0.01 μM, 0.001 μM, the culture medium of the Lycojaponicumin B of 0.0001 μM and 0.00001 μM.After cultivating 48h, add the MTT of concentration 5mg/mL, continue to be put in CO
2incubator cultivates 4h, then 100 μ L supernatants are sucked along culture fluid top, add 100 μ L DMSO, 10min is placed in dark place, microplate reader (Sunrise Products) is utilized to measure light absorption value (wavelength 570nm), and calculating cell survival according to light absorption value, 6 repeating holes are established in each process.Cell survival rate (%)=Δ OD
drug treating/ Δ OD
blank× 100.
2. result: the growth of Lycojaponicumin B to human ileocecal carcinoma cell strain HCT-8 has significant inhibitory action.This compound suppresses the IC of human ileocecal carcinoma cell strain HCT-8 growth
50value is: 1.33 ± 0.11 μMs.
Shown by above-described embodiment, the growth of Lycojaponicumin B of the present invention to human ileocecal carcinoma cell strain HCT-8 has good inhibitory action.Prove thus, it is active that Lycojaponicumin B of the present invention has anti-ileocecum cancer, can for the preparation of anti-blindgut cancer.
Claims (1)
1.Lycojaponicumin B preparation treatment blindgut cancer in application, described compound L ycojaponicumin B structure as
formula Ishown in:
formula I.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201310435560.5A CN103463022B (en) | 2013-09-23 | 2013-09-23 | Application of Lycojaponicumin B in medicine for treating ileocecum cancer |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201310435560.5A CN103463022B (en) | 2013-09-23 | 2013-09-23 | Application of Lycojaponicumin B in medicine for treating ileocecum cancer |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| CN103463022A CN103463022A (en) | 2013-12-25 |
| CN103463022B true CN103463022B (en) | 2015-07-08 |
Family
ID=49788220
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN201310435560.5A Expired - Fee Related CN103463022B (en) | 2013-09-23 | 2013-09-23 | Application of Lycojaponicumin B in medicine for treating ileocecum cancer |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN103463022B (en) |
Citations (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN103059043A (en) * | 2011-10-24 | 2013-04-24 | 中国医学科学院药物研究所 | Clavatine A-C and preparation method as well as pharmaceutical composition and application thereof |
-
2013
- 2013-09-23 CN CN201310435560.5A patent/CN103463022B/en not_active Expired - Fee Related
Patent Citations (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN103059043A (en) * | 2011-10-24 | 2013-04-24 | 中国医学科学院药物研究所 | Clavatine A-C and preparation method as well as pharmaceutical composition and application thereof |
Non-Patent Citations (1)
| Title |
|---|
| "Lycojaponicumins A-C, Three Alkaloids with an Unprecedented Skeleton from Lycopodium japonicum";Xiao-JingWang等;《ORGANIC LETTERS》;20120518;第14卷(第10期);2614-2617 * |
Also Published As
| Publication number | Publication date |
|---|---|
| CN103463022A (en) | 2013-12-25 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CN103463046B (en) | The application of Lycojaponicumin A in preparation treatment colorectal cancer medicine | |
| CN103463022B (en) | Application of Lycojaponicumin B in medicine for treating ileocecum cancer | |
| CN103463045B (en) | The application of Lycojaponicumin A in preparation treatment blindgut cancer | |
| CN103463049B (en) | The application of Lycojaponicumin B in preparation treatment breast cancer medicines | |
| CN103463033B (en) | The application of Lycojaponicumin B in preparation treatment gastric cancer medicament | |
| CN103463059B (en) | The application of Lycojaponicumin B in preparation treatment laryngeal carcinoma medicine | |
| CN103446141B (en) | The application of Lycojaponicumin C in preparation treatment tongue cancer drug | |
| CN103463050B (en) | Application of Lycojaponicumin A in preparation of gastric cancer treatment drug | |
| CN103463056B (en) | The application of Lycojaponicumin A in preparation treatment tongue cancer drug | |
| CN103463051B (en) | The application of Lycojaponicumin A in preparation treatment medicine for nasopharyngeal | |
| CN103463070B (en) | The application of Lycojaponicumin C in preparation treatment breast cancer medicines | |
| CN103463016B (en) | Application of Lycojaponicumin A in preparation of endometrial cancer treatment drug | |
| CN103463047B (en) | The application of Lycojaponicumin B in preparation treatment cancer of biliary duct medicine | |
| CN103446130B (en) | Lycojaponicumin B is preparing the application in Hepatoma therapy medicine | |
| CN103446122B (en) | The application of Lycojaponicumin B in preparation treatment carcinoma of prostate medicine | |
| CN103463027B (en) | The application of Lycojaponicumin A in treatment laryngeal carcinoma medicine | |
| CN103446146B (en) | The application of Lycojaponicumin C in preparation treatment blindgut cancer | |
| CN103463060B (en) | The application of Lycojaponicumin C in preparation treatment endometrial cancer drug | |
| CN103463042B (en) | Application of Lycojaponicumin A in drugs for treating prostatic cancer | |
| CN103463058B (en) | The application of Lycojaponicumin A in treatment cancer of biliary duct medicine | |
| CN103463032B (en) | Application of Lycojaponicumin A in preparation of pancreatic cancer treatment drug | |
| CN103463072B (en) | The application of Lycojaponicumin C in preparation treatment bladder cancer medicine | |
| CN103463069B (en) | The application of Lycojaponicumin C in preparation treatment medicine for nasopharyngeal | |
| CN103463054B (en) | The application of Lycojaponicumin A in preparation treatment bladder cancer medicine | |
| CN103479632B (en) | The application of Lycojaponicumin B in preparation treatment cervical cancer medicine |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| C06 | Publication | ||
| PB01 | Publication | ||
| C10 | Entry into substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| C14 | Grant of patent or utility model | ||
| GR01 | Patent grant | ||
| TR01 | Transfer of patent right |
Effective date of registration: 20171128 Address after: No. 19, Beihai garden shop, No. 99, Yunnan Road, Beihai, the Guangxi Zhuang Autonomous Region Patentee after: Beihai Han Biotechnology Co., Ltd. Address before: Metro Technology Building No. 69 Olympic Avenue in Jianye District of Nanjing city in Jiangsu province 210019 01 5 storey buildings Patentee before: Nanjing Guangkangxie Biomedical Technology Co., Ltd. |
|
| TR01 | Transfer of patent right | ||
| CF01 | Termination of patent right due to non-payment of annual fee |
Granted publication date: 20150708 Termination date: 20190923 |
|
| CF01 | Termination of patent right due to non-payment of annual fee |